Title: Overcoming hurdles developing neuroprotective drugs

Author: Marcel Alavi, Founder of 712 North

Date: 02/27/2018

Brief Description:
712 North is a biopharma developing medical interventions for patients with Alzheimer’s and other forms of dementia. Medicines currently available for this devastating disease only treat the cognitive symptoms, but do not affect the underlying causes of the disorder. We identified a novel mechanism-of-action that can complement all existing efforts to treat Alzheimer’s by studying a rare eye disease called Autosomal Dominant Optic Atrophy. We strongly believe, and as a matter of fact we have the data to support this claim, that whatever helps patients with ADOA will help patients with Alzheimer’s disease as well.

Attachment: